The Clinical Dilemma of Valvular Heart Disease

Transcatheter mitral edge-to-edge repair has transformed therapy for high-risk surgical candidates who suffer from primary mitral regurgitation. Although interventional procedures reliably eliminate mitral backward flow, long-term patient outcomes vary widely across diverse clinical settings. Historically, researchers focused almost exclusively on left ventricular geometry and valvular anatomy to predict post-repair functional recovery. However, right-sided heart pathology plays a decisive role in shaping post-procedural morbidity and overall life expectancy. Concomitant tricuspid regurgitation frequently accompanies mitral valve dysfunction due to shared hemodynamic pathways. Left atrial volume overload increases pulmonary venous pressure, which inevitably strains the compliant right ventricle over time. Consequently, clinicians observe secondary tricuspid annular dilation and leaflet malcoaptation in numerous patients presenting for structural intervention. Despite successful mitral clipping, residual right ventricular failure can trigger refractory congestive symptoms. Furthermore, healthcare teams often struggle to determine whether severe tricuspid regurgitation resolves after mitral repair or requires separate intervention. Recognizing these pathophysiological interactions remains essential for tailoring patient care. Therefore, comprehensive risk stratification demands an in-depth understanding of how baseline right-sided valvular lesions alter survival after transcatheter mitral repair.

PRIME-MR Registry Design and Methodology

To clarify the prognostic impact of right-sided valve disease, investigators analyzed robust data from the PRIME-MR registry. This large multicenter international study evaluated 3,083 patients with severe degenerative mitral disease who underwent edge-to-edge repair between 2008 and 2022. Importantly, twenty-five specialized academic centers across North America and Europe contributed consecutive procedural cases to the collaborative registry. The study investigators restricted this specific analysis to 2,155 patients who achieved procedural success, defined strictly as residual mitral regurgitation of moderate severity or less. Next, researchers stratified the cohort by baseline tricuspid regurgitation severity into two distinct comparative groups. Specifically, eighty percent of the cohort exhibited moderate or less tricuspid regurgitation, while twenty percent presented with severe or greater regurgitation. Baseline evaluations revealed notable differences between these groups before catheter-based intervention. Patients with severe tricuspid regurgitation presented with significantly worse New York Heart Association functional status and shorter six-minute walk distances. In addition, these patients demonstrated higher baseline surgical risk scores and increased circulating natriuretic peptide levels. The researchers tracked all-cause mortality over a rigorous two-year follow-up period to quantify clinical survival differences accurately.

Prognostic Significance of Tricuspid Regurgitation in Primary Mitral Regurgitation

The primary findings from the PRIME-MR registry demonstrated that severe tricuspid regurgitation independently worsens long-term survival in primary mitral regurgitation. Specifically, patients with baseline severe tricuspid regurgitation experienced significantly higher two-year all-cause mortality compared to those with mild or moderate regurgitation. Furthermore, cardiovascular death occurred at an accelerated rate among individuals with advanced right-sided valvular incompetence. Multivariable Cox proportional hazards modeling confirmed that baseline severe tricuspid leak remained an autonomous predictor of death after adjusting for confounding variables. In addition, these high-risk patients experienced frequent hospital readmissions for acute decompensated right heart failure during longitudinal follow-up. Interestingly, successful transcatheter repair produced spontaneous tricuspid regurgitation reduction in nearly thirty percent of affected patients before discharge. This improvement illustrates that relief of left atrial hypertension can elicit rapid hemodynamic unloading of the pulmonary vascular bed. However, approximately seventy percent of patients maintained persistent severe tricuspid regurgitation despite satisfactory mitral repair. Consequently, unresolved right heart overload drove continued symptomatic decline in this substantial patient subset. Thus, these registry observations confirm that severe tricuspid disease represents an ominous prognostic indicator that clinicians cannot overlook.

Mechanisms Driving Right Ventricular Dysfunction

Understanding the biomechanical link between left-sided valvular disease and right ventricular failure explains these stark clinical findings. Chronic mitral regurgitation creates progressive left atrial hypertension, which transmits retrograde backward pressure into the pulmonary venous circulation. Consequently, patients develop reactive pulmonary arterial vasoconstriction and structural vascular remodeling over extended periods. As pulmonary vascular resistance climbs, the thin-walled right ventricle encounters severe afterload mismatch. Initially, right ventricular homeometric compensation preserves forward cardiac output through chamber hypertrophy and adaptive dilation. Over time, however, persistent pressure and volume overload exhaust right ventricular contractile reserve. This progressive dilation enlarges the tricuspid annulus and displaces the papillary muscles, preventing coaptation of the tricuspid valve leaflets. Therefore, functional tricuspid regurgitation develops and initiates a vicious cycle of progressive right-sided volume overload. When structural interventionalists treat mitral regurgitation, left atrial decompression can reverse acute pulmonary venous congestion. Nevertheless, longstanding right ventricular myocardial fibrosis and permanent annular tethering often prevent anatomical recovery. As a result, right ventricular-pulmonary arterial uncoupling persists, causing chronic systemic venous congestion, hepatic dysfunction, and adverse clinical outcomes.

Implications for Multidisciplinary Structural Heart Teams

These landmark registry observations carry profound implications for contemporary clinical practice and structural heart team decision-making. First, heart teams must systematically evaluate right ventricular function and tricuspid valve anatomy during initial patient workups. Comprehensive transthoracic and transesophageal echocardiography should quantify tricuspid regurgitation severity, annular dimensions, and right ventricular-pulmonary arterial coupling. Furthermore, clinicians must recognize that delaying intervention until severe tricuspid regurgitation develops can irreversibly compromise clinical outcomes. In high-risk surgical patients, early transcatheter mitral repair may prevent secondary right heart deterioration before irreversible myocardial damage occurs. Moreover, the emergence of dedicated transcatheter tricuspid repair and replacement devices offers promising new therapeutic pathways. When patients exhibit persistent severe tricuspid regurgitation after mitral repair, structural teams can consider staged transcatheter tricuspid intervention. Alternatively, concurrent transcatheter edge-to-edge repair for both valves may benefit highly selected individuals presenting with dual-valve pathology. Post-procedural management also requires vigilant diuretic titration, neurohormonal optimization, and regular echocardiographic surveillance. Ultimately, adopting a holistic biventricular perspective will enable cardiologists to improve functional capacity, prevent recurrent hospitalizations, and maximize survival in this vulnerable population.

Frequently Asked Questions

Why does tricuspid regurgitation worsen outcomes after mitral transcatheter edge-to-edge repair?

Tricuspid regurgitation reflects significant right ventricular remodeling and pulmonary vascular congestion resulting from prolonged left-sided volume overload. When severe right heart dysfunction develops, correcting mitral leaflet pathology alone cannot fully reverse established hemodynamic impairment. Consequently, persistent systemic venous congestion, hepatic congestion, and cardiorenal interactions exacerbate adverse cardiovascular events. Therefore, concomitant severe tricuspid valve regurgitation portends substantially elevated two-year all-cause mortality and heart failure admissions despite an otherwise technically successful mitral repair.

Can tricuspid regurgitation improve spontaneously following mitral transcatheter edge-to-edge repair?

Yes, tricuspid regurgitation improves spontaneously in approximately thirty percent of affected individuals following successful mitral edge-to-edge repair. Specifically, reducing left atrial pressure and pulmonary venous hypertension promotes acute right ventricular unloading and beneficial reverse remodeling. However, patients with fixed pulmonary hypertension, chronic atrial fibrillation, or marked tricuspid annular dilation rarely experience meaningful spontaneous recovery. Therefore, clinicians must carefully track postoperative echocardiographic parameters to identify persistent severe regurgitation requiring subsequent transcatheter tricuspid intervention.

Should interventional cardiologists treat tricuspid regurgitation concurrently during mitral edge-to-edge repair?

Currently, clinical evidence supports a staged or selective combined approach based on individual anatomy and surgical risk. While addressing primary mitral regurgitation provides significant forward hemodynamic relief, seventy percent of patients with baseline severe tricuspid regurgitation exhibit persistent leak. Consequently, multidisciplinary structural heart teams increasingly evaluate patients for concurrent or staged transcatheter tricuspid repair. As dedicated transcatheter tricuspid devices proliferate, timely combined transcatheter intervention may mitigate ongoing right-sided failure and improve long-term functional survival.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Scotti A et al. Impact of Tricuspid Regurgitation on Outcomes After Transcatheter Edge-to-Edge Repair for Primary Mitral Regurgitation: The PRIME-MR Registry. Circ Cardiovasc Interv. 2026 Sep 11. doi: 10.1161/CIRCINTERVENTIONS.126.016634. PMID: 42723620.


2. Kalbacher D, Schäfer U, von Bardeleben RS, et al. Impact of tricuspid valve regurgitation in surgical high-risk patients undergoing MitraClip implantation: results from the TRAMI registry. EuroIntervention. 2017;12(15):e1809-e1816.


3. Chitturi KR, Bhardwaj B, Mills J, et al. Clinical Impact of Tricuspid Regurgitation on Transcatheter Edge-to-Edge Mitral Valve Repair for Mitral Regurgitation. Cardiovasc Revasc Med. 2022;40:154-161.